CureVac rejects exclusive contract for Covid-19 vaccine for the USA

According to a report in the newspaper “Mannheimer Morgen”, an exclusive contract with the USA for a Covid-19 vaccine is out of the question for the Tübingen-based pharmaceutical company CureVac.

Thorsten Benner
@thorstenbenner German officials alarmed over what they see as Trump’s aggressive 1bn US$ bid to take over Tübingen-based biopharmaceutical company Curevac to secure possible COVID19 vaccine “just for US”. Officials to offer incentives to Curevac & consider blocking sale.

Mar-15,2020 16:18
Likes:1,793   Retweets:1,725

The Tübingen-based company CureVac, which is working on a coronavirus vaccine, will not be sold to the USA, said Federal Minister of Economics Peter Altmaier (CDU) on ARD television.

“We want to develop a vaccine for the whole world and not for individual countries,” Christof Hettich, CEO and co-founder of the main investor dievini Hopp BioTech Holding, told the newspaper.

SAP co-founder and patron Dietmar Hopp and entrepreneur Friedrich von Bohlen are also among the founders and managing directors. Since January, the pharmaceutical company CureVac has been researching a vaccine against the novel coronavirus.

In addition, Hopp is resolutely committed to the company, its employees and its headquarters in Tübingen, Hettich continued. According to a report in the “Welt am Sonntag” newspaper, there are disputes between Germany and the USA about the Tübingen-based company.

US President Donald Trump is trying to lure German scientists to America with large financial contributions or to secure the drug exclusively for his country, the newspaper reported, citing government circles in Berlin.

The report itself says only that the US was seeking an “exclusive license” but did not say what that license was for (e.g. to buy, to make, to sell, etc)

1 Comment

Leave a Reply

Your email address will not be published.